# Auburn National Bancorporation, Inc: financial statements, quarterly

AUBN · Nasdaq · CIK 750574 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aubn.md) · [Financials](/companies/aubn/financials.md) · [Filings](/companies/aubn/filings.md) · [Insiders](/companies/aubn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aubn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [148](/filings/0001193125-24-249547.md) | [147 d](/filings/0001193125-25-051574.md) | [156](/filings/0001193125-25-111182.md) | [153](/filings/0001193125-25-178717.md) | [154](/filings/0001193125-25-277883.md) | [151 d](/filings/0001193125-26-111012.md) | [155](/filings/0001193125-26-221544.md) | [152](/filings/0001193125-26-345021.md) | [154](/filings/0001193125-25-277883.md) | [158 d](/filings/0001193125-26-111012.md) | [153](/filings/0001193125-26-221544.md) | [153](/filings/0001193125-26-345021.md) |
| Interest expense | $k | [2,371](/filings/0001193125-24-249547.md) | [3,044 d](/filings/0001193125-25-051574.md) | [2,572](/filings/0001193125-25-111182.md) | [2,875](/filings/0001193125-25-178717.md) | [3,169](/filings/0001193125-25-277883.md) | [2,991 d](/filings/0001193125-26-111012.md) | [2,816](/filings/0001193125-26-221544.md) | [2,767](/filings/0001193125-26-345021.md) | [2,840](/filings/0001193125-25-277883.md) | [2,671 d](/filings/0001193125-26-111012.md) | [2,628](/filings/0001193125-26-221544.md) | [2,692](/filings/0001193125-26-345021.md) |
| Income tax | $k | [182](/filings/0001193125-24-249547.md) | [(1,514) d](/filings/0001193125-25-051574.md) | [164](/filings/0001193125-25-111182.md) | [475](/filings/0001193125-25-178717.md) | [531](/filings/0001193125-25-277883.md) | [830 d](/filings/0001193125-26-111012.md) | [392](/filings/0001193125-26-221544.md) | [485](/filings/0001193125-26-345021.md) | [623](/filings/0001193125-25-277883.md) | [456 d](/filings/0001193125-26-111012.md) | [603](/filings/0001193125-26-221544.md) | [611](/filings/0001193125-26-345021.md) |
| Net income | $k | [1,488](/filings/0001193125-24-249547.md) | [(3,985) d](/filings/0001193125-25-051574.md) | [1,371](/filings/0001193125-25-111182.md) | [1,734](/filings/0001193125-25-178717.md) | [1,732](/filings/0001193125-25-277883.md) | [1,560 d](/filings/0001193125-26-111012.md) | [1,530](/filings/0001193125-26-221544.md) | [1,833](/filings/0001193125-26-345021.md) | [2,227](/filings/0001193125-25-277883.md) | [1,665 d](/filings/0001193125-26-111012.md) | [2,198](/filings/0001193125-26-221544.md) | [2,298](/filings/0001193125-26-345021.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | [0.50](/filings/0001193125-25-277883.md) | not reported | [0.44](/filings/0001193125-26-221544.md) | [0.52](/filings/0001193125-26-345021.md) | [0.64](/filings/0001193125-25-277883.md) | not reported | [0.63](/filings/0001193125-26-221544.md) | [0.66](/filings/0001193125-26-345021.md) |
| Basic EPS | $ per share | [0.43](/filings/0001193125-24-249547.md) | not reported | [0.39](/filings/0001193125-25-111182.md) | [0.50](/filings/0001193125-25-178717.md) | [0.50](/filings/0001193125-25-277883.md) | not reported | [0.44](/filings/0001193125-26-221544.md) | [0.52](/filings/0001193125-26-345021.md) | [0.64](/filings/0001193125-25-277883.md) | not reported | [0.63](/filings/0001193125-26-221544.md) | [0.66](/filings/0001193125-26-345021.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [1,031](/filings/0001193125-23-272449.md) | [975](/filings/0001193125-25-051574.md) | [979](/filings/0001193125-24-134060.md) | [1,025](/filings/0001193125-24-192937.md) | [990](/filings/0001193125-24-249547.md) | [977](/filings/0001193125-26-111012.md) | [997](/filings/0001193125-25-111182.md) | [1,029](/filings/0001193125-25-178717.md) | [1,011](/filings/0001193125-25-277883.md) | [1,019](/filings/0001193125-26-345021.md) | [1,027](/filings/0001193125-26-221544.md) | [1,086](/filings/0001193125-26-345021.md) |
| Total liabilities | $m | [969](/filings/0001193125-23-272449.md) | [899](/filings/0001193125-25-051574.md) | [905](/filings/0001193125-24-134060.md) | [950](/filings/0001193125-24-192937.md) | [906](/filings/0001193125-24-249547.md) | [899](/filings/0001193125-26-111012.md) | [914](/filings/0001193125-25-111182.md) | [943](/filings/0001193125-25-178717.md) | [922](/filings/0001193125-25-277883.md) | [927](/filings/0001193125-26-345021.md) | [934](/filings/0001193125-26-221544.md) | [992](/filings/0001193125-26-345021.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [61.5](/filings/0001193125-24-249547.md) | [76.5](/filings/0001193125-26-111012.md) | [74.5](/filings/0001193125-25-178717.md) | [75.2](/filings/0001193125-25-277883.md) | [84.3](/filings/0001193125-25-277883.md) | [78.3](/filings/0001193125-26-345021.md) | [83.1](/filings/0001193125-26-345021.md) | [86.1](/filings/0001193125-26-345021.md) | [89.6](/filings/0001193125-25-277883.md) | [92.1](/filings/0001193125-26-345021.md) | [93.1](/filings/0001193125-26-345021.md) | [93.9](/filings/0001193125-26-345021.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [3,318 d](/filings/0001193125-24-249547.md) | [1,209 d](/filings/0001193125-25-051574.md) | [3,081](/filings/0001193125-25-111182.md) | [3,055 d](/filings/0001193125-25-178717.md) | [1,873 d](/filings/0001193125-25-277883.md) | [2,800 d](/filings/0001193125-26-111012.md) | [2,627](/filings/0001193125-26-221544.md) | [2,137 d](/filings/0001193125-26-345021.md) | [4,085 d](/filings/0001193125-25-277883.md) | [3,500 d](/filings/0001193125-26-111012.md) | [2,535](/filings/0001193125-26-221544.md) | [1,511 d](/filings/0001193125-26-345021.md) |
| Share repurchases | $k | [130 d](/filings/0001193125-24-249547.md) | [0.0 d](/filings/0001193125-25-051574.md) | [0.0](/filings/0001193125-24-134060.md) | [0.0 d](/filings/0001193125-24-192937.md) | [0.0 d](/filings/0001193125-24-249547.md) | [0.0 d](/filings/0001193125-25-051574.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [3,494](/filings/0001193125-25-277883.md) | [3,494](/filings/0001193125-26-221544.md) | [3,494](/filings/0001193125-26-345021.md) | [3,496](/filings/0001193125-25-277883.md) | [3,497](/filings/0001193125-26-221544.md) | [3,492](/filings/0001193125-26-345021.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,484,292 at 2026-08-10, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-345021.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.